| pubmed-article:8618109 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8618109 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8618109 | lifeskim:mentions | umls-concept:C1541907 | lld:lifeskim |
| pubmed-article:8618109 | lifeskim:mentions | umls-concept:C0684224 | lld:lifeskim |
| pubmed-article:8618109 | lifeskim:mentions | umls-concept:C0678226 | lld:lifeskim |
| pubmed-article:8618109 | lifeskim:mentions | umls-concept:C0439611 | lld:lifeskim |
| pubmed-article:8618109 | lifeskim:mentions | umls-concept:C0055005 | lld:lifeskim |
| pubmed-article:8618109 | pubmed:dateCreated | 1996-6-7 | lld:pubmed |
| pubmed-article:8618109 | pubmed:abstractText | Penicillin therapy has considerably reduced the occurrence of serious late complications of streptococcal pharyngotonsillitis. However, treatment failure with this antibiotic is currently reported in up to 30% of the cases. Beta-lactamase production by the commensal flora of the tonsils, and poor compliance of patients have been implicated as the main causes of treatment failure. Cefetamet pivoxil is a new oral cephalosporin with a twice daily dosage and striking stability against beta-lactamases. We are conducting a prospective, randomized study in 120 children, comparing the efficacy of cefetamet pivoxil 10 mg/kg bid for 5 and 10 days and phenoxymethyl penicillin 25,000 U/kg tid for 10 days in the treatment of group A beta-hemolytic streptococcus (GABHS) pharyngotonsillitis. Children are enrolled after the positive culture of a throat swab and randomly assigned to one of the three groups. A follow-up check-up is performed at the end of the therapy (clinical check-up) and 3 to 5 days later (bacteriological check-up). The preliminary analysis of 55 cases shows that in 88.9%, 100% and 87.5% of children GABHS was eradicated by 5 days or 10 days of cefetamet pivoxil, or 10 days of penicillin respectively (p = NS). Side effect were mild and transient in cefetamet pivoxil-treated patients, but required cessation of treatment in 2 children treated with penicillin. These results suggest that cefetamet pivoxil therapy for 5 days eradicates GABHS from the throat in streptococcal pharyngotonsillitis as efficiently as cefetamet pivoxil or phenoxymethyl penicillin for 10 days. | lld:pubmed |
| pubmed-article:8618109 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8618109 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8618109 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8618109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8618109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8618109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8618109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8618109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8618109 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8618109 | pubmed:month | May | lld:pubmed |
| pubmed-article:8618109 | pubmed:issn | 1120-009X | lld:pubmed |
| pubmed-article:8618109 | pubmed:author | pubmed-author:GervaisFF | lld:pubmed |
| pubmed-article:8618109 | pubmed:author | pubmed-author:SuterSS | lld:pubmed |
| pubmed-article:8618109 | pubmed:author | pubmed-author:HalpérinD SDS | lld:pubmed |
| pubmed-article:8618109 | pubmed:author | pubmed-author:BrightYY | lld:pubmed |
| pubmed-article:8618109 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8618109 | pubmed:volume | 7 Suppl 1 | lld:pubmed |
| pubmed-article:8618109 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8618109 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8618109 | pubmed:pagination | 21-4 | lld:pubmed |
| pubmed-article:8618109 | pubmed:dateRevised | 2009-8-4 | lld:pubmed |
| pubmed-article:8618109 | pubmed:meshHeading | pubmed-meshheading:8618109-... | lld:pubmed |
| pubmed-article:8618109 | pubmed:meshHeading | pubmed-meshheading:8618109-... | lld:pubmed |
| pubmed-article:8618109 | pubmed:meshHeading | pubmed-meshheading:8618109-... | lld:pubmed |
| pubmed-article:8618109 | pubmed:meshHeading | pubmed-meshheading:8618109-... | lld:pubmed |
| pubmed-article:8618109 | pubmed:meshHeading | pubmed-meshheading:8618109-... | lld:pubmed |
| pubmed-article:8618109 | pubmed:meshHeading | pubmed-meshheading:8618109-... | lld:pubmed |
| pubmed-article:8618109 | pubmed:meshHeading | pubmed-meshheading:8618109-... | lld:pubmed |
| pubmed-article:8618109 | pubmed:meshHeading | pubmed-meshheading:8618109-... | lld:pubmed |
| pubmed-article:8618109 | pubmed:meshHeading | pubmed-meshheading:8618109-... | lld:pubmed |
| pubmed-article:8618109 | pubmed:meshHeading | pubmed-meshheading:8618109-... | lld:pubmed |
| pubmed-article:8618109 | pubmed:meshHeading | pubmed-meshheading:8618109-... | lld:pubmed |
| pubmed-article:8618109 | pubmed:meshHeading | pubmed-meshheading:8618109-... | lld:pubmed |
| pubmed-article:8618109 | pubmed:meshHeading | pubmed-meshheading:8618109-... | lld:pubmed |
| pubmed-article:8618109 | pubmed:meshHeading | pubmed-meshheading:8618109-... | lld:pubmed |
| pubmed-article:8618109 | pubmed:meshHeading | pubmed-meshheading:8618109-... | lld:pubmed |
| pubmed-article:8618109 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8618109 | pubmed:articleTitle | Cefetamet pivoxil in the treatment of pharyngotonsillitis due to group A beta-hemolytic streptococci: preliminary report. | lld:pubmed |
| pubmed-article:8618109 | pubmed:affiliation | Department of Pediatrics, Hôpital Cantonal Universitaire, Geneva, Switzerland. | lld:pubmed |
| pubmed-article:8618109 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8618109 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8618109 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:8618109 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
